The Takeda-backed gastrointestinal disease therapy developer has boosted its initial public offering to $209m after its shares rose 23% post-flotation.

The Novo and Novartis-backed company, which is developing drugs to make radiotherapy less harmful, is set to raise between $70m and $80m.

Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.

GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.

Returning investor Lilly Asia Ventures contributed to a $62m series D round for contract pharmaceutical researcher Fountain Medical Development that was led by Goldman Sachs.

LivaNova participated in a series A round for Shiratronics that will fund the progression of its migraine headache treatment device toward clinical testing.

Sumitomo Corporation of Americas contributed to the latest round for healthcare consulting services provider Avia, which already has several care providers as investors.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The stroke measurement software provider Viz.ai has now raised more than $78m, pulling in funding through a GV-backed series B round.